Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04930432 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 78 to 87 Eligibility criteria expanded, about 145 wordsv4 Show 1 more changeShow less
    • Eligibility criteria expanded, about 145 words

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Jun 30, 2024 to Apr 30, 2028 Study sites: 64 to 78 · Completion date: Jun 30, 2025 to Dec 30, 2028 · Eligibility criteria shortened, about 18 words · 3 morev3 Show 6 more changesShow less
    • Study sites: 64 to 78
    • Completion date: Jun 30, 2025 to Dec 30, 2028
    • Eligibility criteria shortened, about 18 words
    • Secondary endpoints: 19 to 15
    • Study description expanded, about 95 words
    • Study arms: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 64 · Start date changed from estimate of Jul 1, 2021 to Sep 24, 2021v2 Show 2 more changesShow less
    • Study sites: 1 to 64
    • Start date changed from estimate of Jul 1, 2021 to Sep 24, 2021
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-center, open-label, Phase I/II clinical study of MCLA-129 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics and antitumor activity of MCLA-129.
Trial Details
NCT Number NCT04930432
Lead Sponsor Betta Pharmaceuticals Co., Ltd.
Conditions Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov